K
Kenji Tamura
Researcher at Osaka Medical College
Publications - 285
Citations - 9293
Kenji Tamura is an academic researcher from Osaka Medical College. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 39, co-authored 262 publications receiving 6174 citations.
Papers
More filters
Journal ArticleDOI
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi,Cristina Saura,Toshinari Yamashita,Yeonhee Park,Sung Bae Kim,Kenji Tamura,Fabrice Andre,Hiroji Iwata,Yoshinori Ito,Junji Tsurutani,Junji Tsurutani,Joohyuk Sohn,Neelima Denduluri,Christophe Perrin,Kenjiro Aogi,Eriko Tokunaga,Seock-Ah Im,Keun Seok Lee,Sara A. Hurvitz,Javier Cortes,Caleb Lee,Shuquan Chen,Lin Zhang,Javad Shahidi,Antoine Yver,Ian E. Krop +25 more
TL;DR: Tastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer and requires attention to pulmonary symptoms and careful monitoring.
Journal ArticleDOI
Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells
Makiko Ono,Nobuyoshi Kosaka,Naoomi Tominaga,Yusuke Yoshioka,Fumitaka Takeshita,Ryou U. Takahashi,Masayuki Yoshida,Hitoshi Tsuda,Kenji Tamura,Takahiro Ochiya +9 more
TL;DR: Findings suggest that exosomal transfer of miRNAs from the bone marrow may promote breast cancer cell dormancy in a metastatic niche.
Journal ArticleDOI
Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood–brain barrier
Naoomi Tominaga,Nobuyoshi Kosaka,Makiko Ono,Takeshi Katsuda,Yusuke Yoshioka,Kenji Tamura,Jan Lötvall,Hitoshi Nakagama,Takahiro Ochiya +8 more
TL;DR: It is shown that cancer-derived extracellular vesicles, mediators of cell–cell communication via delivery of proteins and microRNAs (miRNAs), trigger the breakdown of BBB, and that systemic injection of brain metastatic cancer cell-derived EVs promoted brain metastasis of breast cancer cell lines and are preferentially incorporated into the brain in vivo.
Journal ArticleDOI
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
Sylvia Adams,Sherene Loi,Deborah Toppmeyer,David W. Cescon,M. De Laurentiis,Rita Nanda,EP Winer,Hirofumi Mukai,Kenji Tamura,Anne C Armstrong,Minetta C. Liu,H. Iwata,Larisa Ryvo,Pauline Wimberger,Hope S. Rugo,Antoinette R. Tan,L. Jia,Y. Ding,Vassiliki Karantza,Peter Schmid +19 more
TL;DR: Pembrolizumab monotherapy had a manageable safety profile and showed durable antitumor activity as first-line therapy for patients with PD-L1-positive mTNBC.
Journal ArticleDOI
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Shanu Modi,Haeseong Park,Rashmi Krishna Murthy,Hiroji Iwata,Kenji Tamura,Junji Tsurutani,Alvaro Moreno-Aspitia,Toshihiko Doi,Yasuaki Sagara,Charles H. Redfern,Ian E. Krop,Caleb Lee,Yoshihiko Fujisaki,Masahiro Sugihara,Lin Zhang,Javad Shahidi,Shunji Takahashi +16 more
TL;DR: The novel Her2-targeted ADC, T-DXd, demonstrated promising preliminary antitumor activity in patients with HER2-low breast cancer and should be monitored closely and proactively managed.